drugset / Trial / NCT05622500

Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease

NCT05622500 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Chronic obstruction of the iliac veins or inferior vena cava can occur as a result of deep vein thrombosis (DVT), or due to extrinsic compression in non-thrombotic iliac vein lesions (NIVLs). This obstruction can manifest as post-thrombotic syndrome (PTS) after DVT or as chronic venous disease (CVD) in NIVL. Despite sparse evidence, rates of venous stenting for PTS and NIVLs are increasing. A pragmatic, observer-blind, multi-centre, randomised-controlled trial for adults with CVD secondary to either PTS or NIVLs randomised to either best endovenous therapy (including venoplasty and deep venous stenting) or standard therapy (compression +/- anticoagulation). Included participants will have chronic venous disease (CEAP classification 3 - 6) secondary to proximal deep venous disease. The primary outcome is severity of venous disease at 6 months as ascertained by the Venous Clinical Severity Score (VCSS).

Timeline

Start
2022-09-03
Primary completion
2025-04-08
Completion
2025-04-08

Outcome

Outcome not reported

Stopped (Enrollment): “The trial failed to meet the milestones in the internal pilot of feasibility. The trial was redesigned to improve its deliverability and reduce burden to sites prior to being relaunched. Unfortunately, the trial failed to sufficiently recruit.”

Drugs

EvaluationDrugModalityDoseRoute
Background Apixaban Small molecule — —
Background Aspirin Small molecule — —
Background Clopidogrel Small molecule — —
Background Rivaroxaban Other / unclassified — —
Background Warfarin Small molecule — —